Citations

Clear

1792 citation(s) found for "Stephanie".

Comparative Analysis of Injury and Illness Rates Among Team USA Athletes at the Tokyo 2020 Summer Olympic and Paralympic Games
Post, Eric G. , Cali, Malia G. , Clark, Stephanie C., Noble-Taylor, Kayle E., Robinson, David M. , Hasley, Ike B., Larson, Emily G., McPherson, April L. , Adams, William M. , Adams, William M , Clark, Stephanie C., Robinson, David M., Anderson, Travis , Finnoff, Jonathan T.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 2, 2025 | Volume: 13 | Issue: 1 | Pages: No page available

10.1177/23259671241304417 | PMID 39758142 Get It

Background: Previous research has reported higher rates of both injury and illness among Paralympic athletes compared with Olympic athletes during the Winter Olympic and Paralympic Games, but no studies have directly compared injury and illness incidence between Olympic and Paralympic athletes competing in a Summer Games. Purpose: To compare injury and illness rates between Olympic and Paralympic Team USA athletes competing in the Tokyo 2020 Olympic and Paralympic Games. Study Design: Descriptive epidemiology study. Methods: All injuries and illnesses that occurred among the Team USA athletes competing in the Tokyo 2020 Summer Olympic or Paralympic Games were documented. A total of 701 Team USA athletes (53.6% female) competed in the Tokyo 2020 Summer Olympic Games, across 34 different sports. For the Tokyo 2020 Summer Paralympic Games, a total of 245 athletes (51.6% female) competed across 20 sports. Incidence rates (IRs) per 1000 athlete-days were calculated according to sex, sport, anatomic location, and illness type. IR ratios (IRRs) were calculated to compare IRs between male and female athletes and between Olympic and Paralympic athletes. Results: Overall, there were no differences in injury incidence (IRR, 1.18; 95% CI, 0.84-1.68) or illness incidence (IRR, 0.68; 95% CI, 0.41-1.15) between Olympic and Paralympic athletes. Male Paralympic athletes were less likely to sustain an illness compared with female Paralympic athletes (IRR, 0.35; 95% CI, 0.11-0.90). Conclusion: There were no differences in injury or illness rates between Olympic and Paralympic Team USA athletes competing at the Tokyo 2020 Summer Games, contrary to previous comparisons among winter sport athletes. These results challenge the prevailing notion that Summer Paralympic athletes are at greater injury and illness risk, suggesting that factors beyond Olympic or Paralympic Games participation influence health concerns.
DEK::AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma
Hart, Stephanie A , Mikula, Michael W. , Amin, Sara E. , Saluja, Karan , Chen, Y., David, Stephanie N., Dupont, William D., Plummer, W. Dale, Ferrer, Karen, Geromes, Ariana, Hsieh, Min-Shu, Kuo, Ying‐Ju , Sasaki, Eiichi , Shi, Qiuying , Truong, Tra , Lewis, James S. , Lewis, James S , Hang, Jen‐Fan , Chernock, Rebecca , Rooper, Lisa M. , Bishop, Justin A. , Cipriani, Nicole A. , Hsieh, Min‐Shu , Hernandez‐Prera, Juan C. , Torres, Jaylou M. Velez

Mayo Clinic

American Journal of Surgical Pathology | December 25, 2024 | Volume: 49 | Issue: 2 | Pages: 130-137

10.1097/pas.0000000000002335 | PMID 39719672 Get It

DEK::AFF2 fusion nonkeratinizing squamous cell carcinoma (NKSCC) is an emerging entity in the sinonasal tract, temporal bone, and skull base. However, the clinical behavior of these tumors has not been well studied. Here, we report the largest cohort of DEK::AFF2 carcinomas to determine if morphology, mitotic rate, and/or Ki-67 IHC are associated with patient outcomes, including a comparison with high-risk human papillomavirus (HPV)-associated and independent patients. We solicited cases of molecularly or AFF2 immunohistochemistry (IHC) proven DEK::AFF2 SCC from surgical pathologists to collect patient demographic, clinical, and outcome data. Using representative H&E slides, we characterized the morphology and counted mitoses. Ki-67 immunohistochemistry was performed. We also compared the DEK::AFF2 survival rates to those in a cohort of AFF2 IHC-negative HPV-associated and HPV-independent SCC. DEK::AFF2 carcinomas most commonly arose in the nasal cavity (13/30, 43%), and the average number of recurrences was 1.8 (range: 0 to 10). At the last follow-up, most patients were disease free (19/30, 63%) or were alive with disease (9/30, 30%). There was an average mitotic rate of 2 per 2 mm2 (range: 0 to 9) and Ki-67 proliferation rate of 26% (range: 3% to 60%). Local recurrence was common, but morphology, mitotic activity, and Ki-67 index were not associated with recurrence or survival. On Kaplan-Meier survival analysis, DEK::AFF2 patients had lower disease-free survival but otherwise had similar outcomes to conventional SCC patients. Our multi-institutional study shows that local recurrence is common in DEK::AFF2 fusion nonkeratinizing SCC patients, but patients have survival rates similar to conventional SCC. Despite showing a range of different features and proliferation rates, traditional grading by morphology, mitotic rate, and/or Ki-67 activity does not seem to be predictive of outcome.
Multicohort Analysis of Bronchial Epithelial Cell Expression in Healthy Subjects and Patients with Asthma Reveals Four Clinically Distinct Clusters
Lee, Ian , Ganesan, Ananthakrishnan , Kalesinskas, Laurynas , Zheng, Hong , Ahn, Haejun C., Christenson, S., Erzurum, Serpil C. , Zein, Joe , Bleecker, Eugene R., Meyers, Deborah A., Fahy, John V. , Israel, Elliot, Jarjour, Nizar N. , Moore, W., Mauger, David T. , Woodruff, Prescott G. , Ortega, Victor E. , Khatri, Purvesh , Zheng, Hong , Lee, Ian , Christenson, Stephanie A. , Castro, M , Wenzel, Sally E , Khatri, Purvesh , Lee, Ian Y , Christenson, Stephanie A , Lee, Ian , Meyers, Deborah A. , Castro, Mario , Israel, Elliot , Wenzel, Sally E. , Levy, Bruce David

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | December 19, 2024 | Volume: 73 | Issue: 1 | Pages: 73-87

10.1165/rcmb.2024-0125oc | PMID 39700523 Get It

Abstract Asthma is a heterogeneous disease with variable presentation and characteristics. There is a critical need to identify underlying molecular endotypes of asthma. We performed the largest transcriptomic analysis of 808 bronchial epithelial cell samples across 11 independent cohorts, including 3 cohorts from the Severe Asthma Research Program. Using seven datasets (218 patients with asthma, 148 healthy control subjects) as discovery cohorts, we identified 505 differentially expressed genes, which we validated in the remaining four datasets. Unsupervised clustering using the 505 differentially expressed genes identified four reproducible clusters of patients with asthma across all datasets, corresponding to healthy control subjects, patients with mild/moderate asthma, and patients with severe asthma with significant differences in several clinical markers of severity, including pulmonary function, Type 2 inflammation, fractional exhaled nitric oxide, and maximum bronchodilator reversibility. Importantly, we found the same clusters in pediatric patients using nasal lavage fluid cells, demonstrating the gene signature and clusters are not confounded by age and are conserved in both lower and upper airways. The four asthma clusters may represent a unifying framework for understanding the molecular heterogeneity of asthma. Further study could potentially enable a precision medicine approach of matching therapies with patients with asthma most likely to benefit.
Diagnostic test accuracy of self-administered cognitive assessment tools for dementia
Naeem, Fariha , McCleery, Jenny, Hietamies, Tuuli M, Ismail, Fatene Abakar , Clinton, Stephanie, O’Mahony, Aoife , Ponce, Oscar J. , Quinn, Terry , Ponce, Oscar Josue

Mayo Clinic

Cochrane Database of Systematic Reviews | December 19, 2024 | Volume: 2024 | Issue: 12 | Pages: No page available

10.1002/14651858.cd013725.pub2 | PMID 39698927 Get It

Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference
Kloske, Courtney M. , Batista, André F., Carrillo, María C. , Chakrabarty, Paramita , Chen, Xiaoying , Craft, Suzanne , Mesquita, Sandro Dá , Devanand, Davangere P. , Durán‐Laforet, Violeta , Fitzgerald‐Bocarsly, Patricia , Hong, Soyon , Jackvony, Stephanie , Lai, Laijun , Liddelow, Shane A. , Martín‐Peña, Alfonso , Orr, Anna G. , Quintana, Francisco José López , Ramey, G. , Sexton, Claire E. , Torrellas, Jose, Tsai, Andy P. , Wharton, Whitney , Da Mesquita, Sandro , Mahinrad, Simin , Barnum, Christopher J. , Bradshaw, Elizabeth M. , Butts, Brittany , Dabin, Luke Child , Elyaman, Wassim , Evans, Elizabeth E. , Foley, Kate E. , Harms, Ashley S. , Heneka, Michael T. , Huang, Yu‐Wen Alvin , Le Guen, Yann , Lemere, Cynthia Ann , Quintana, Francisco J., Rexach, Jessica E. , Rizzo, Stacey J. Sukoff , Tang, Alice , Olst, Lynn van , Walker, Keenan A. , Tansey, Malú G. , Wilcock, Donna M.

Mayo Clinic

Alzheimer's & Dementia | December 18, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14291 | PMID 39692624 Get It

Abstract The immune system is a key player in the onset and progression of neurodegenerative disorders. While brain resident immune cell‐mediated neuroinflammation and peripheral immune cell (eg, T cell) infiltration into the brain have been shown to significantly contribute to Alzheimer's disease (AD) pathology, the nature and extent of immune responses in the brain in the context of AD and related dementias (ADRD) remain unclear. Furthermore, the roles of the peripheral immune system in driving ADRD pathology remain incompletely elucidated. In March of 2023, the Alzheimer's Association convened the Alzheimer's Association International Conference (AAIC), Advancements: Immunity, to discuss the roles of the immune system in ADRD. A wide range of topics were discussed, such as animal models that replicate human pathology, immune‐related biomarkers and clinical trials, and lessons from other fields describing immune responses in neurodegeneration. This manuscript presents highlights from the conference and outlines avenues for future research on the roles of immunity in neurodegenerative disorders. Highlights The immune system plays a central role in the pathogenesis of Alzheimer's disease. The immune system exerts numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The 2023 AAIC, Advancements: Immunity, encouraged discussions and collaborations on understanding the role of the immune system.
Health care concerns in women at midlife: differences by race, ethnicity, and neighborhood socioeconomic status
Kapoor, Ekta , MacLaughlin, Kathy L. , Jiang, Ruoxiang , Rocca, Walter A. , St Sauver, Jennifer L , Bielinski, Suzette J. , Sauver, Jennifer L. St. , Kapoor, Ekta , Faubion, Stephanie S.

Mayo Clinic

Menopause | December 17, 2024 | Volume: 32 | Issue: 2 | Pages: 112-120

10.1097/gme.0000000000002468 | PMID 39689245 Get It

Abstract Objectives The aims of the study were to identify conditions diagnosed in at least 10% of midlife women living in the US upper midwest and to assess prevalence by age, race, ethnicity, and sociodemographic status. Methods The Rochester Epidemiology Project was used to conduct a cross-sectional prevalence study of 86,946 women between 40 and 59 years residing in a 27-county region of the United States on January 1, 2020. Diagnostic billing codes were extracted and grouped into broader condition categories using the Clinical Classification System Refined. The prevalence of 424 conditions was calculated by age, race, ethnicity, and area deprivation index quartiles. Logistic regression was used to examine associations between participant characteristics and conditions that affected 10% or more of the study population. Results Twenty-eight conditions affected ≥10% of women, and eight conditions increased by ≥45% between the ages of 40 and 59 (disorders of lipid metabolism, hypertension, sleep/wake disorders, thyroid disorders, esophageal disorders, osteoarthritis, tendon and synovial disorders, and menopausal disorders; all test for trend P < 0.01). Black women had a significantly higher prevalence of hypertension and esophageal disorders at all ages (adjusted P values <0.05). Women living in more deprived areas had a significantly higher prevalence of hyperlipidemia, hypertension, sleep/wake disorders, and esophageal disorders (adjusted P values <0.05). Women living in less deprived areas had a significantly higher prevalence of thyroid disorders at age 40 to 44 and menopausal disorders at ages 50 to 59 (adjusted P values <0.05). Conclusions These data suggest that additional attention should focus on Black women and women with a lower socioeconomic status to ensure that common midlife conditions are diagnosed and treated.
The association between metabolic dysfunction–associated steatotic liver disease diagnosis and vasomotor symptoms in midlife women
Kapoor, Ekta , Cole, Kristin , Hedges, Mary S. , Mara, Kristin C. , Aldhaleei, Wafa A , Mara, Kristin C , Hedges, Mary S , Aldhaleei, Wafa Ali , Kapoor, Ekta , Shufelt, Chrisandra , Wallace, Michael B. , Kling, Juliana M. , Winham, Stacey J. , Faubion, Stephanie S.

Mayo Clinic

Menopause | December 17, 2024 | Volume: 32 | Issue: 2 | Pages: 121-127

10.1097/gme.0000000000002460 | PMID 39689247 Get It

Abstract Objective Metabolic dysfunction–associated steatotic liver disease (MASLD) and vasomotor symptoms (VMS) are associated with increased cardiovascular disease risk. Although visceral adiposity has been linked to MASLD and VMS independently, this study aimed to evaluate associations between the two in midlife women. Methods A cross-sectional study of women aged 45-60 years receiving primary care at one of four sites was conducted from March 1 through June 30, 2021. MASLD diagnosis was obtained utilizing the International Classification of Diseases , Ninth Revision and Tenth Revision codes. VMS burden was evaluated with the Menopause Rating Scale and categorized as severe/very severe versus none/mild/moderate. Logistic regression models were used to assess the association between VMS and diagnosed MASLD both univariately and after individually adjusting for several risk factors. Results A total of 4,599 women were included in the final analysis, 304 (7%) of whom had an MASLD diagnosis. On univariate analysis, women with an MASLD diagnosis were more likely to have severe/very severe VMS (odds ratio [OR], 1.50; 95% CI, 1.08-2.08; P = 0.015). However, the association between MASLD diagnosis and severe/very severe VMS was no longer statistically significant after individually adjusting for body mass index (adjusted OR, 1.36; 95% CI, 0.97-1.92) and hypertension (adjusted OR, 1.38; 95% CI, 0.99-1.93). Conclusions The relationship between MASLD and VMS appears to be best explained by other variables including BMI and hypertension. Although they do not appear to be directly linked, given the prevalence of bothersome VMS in midlife women, addressing VMS may enable greater adherence to lifestyle modifications as part of MASLD management.
Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
Milne, Roger L. , John, Esther M. , Andrulis, Irene L., Colonna, Sarah V. , Phillips, Kelly‐Anne , Investigators, kConFab, Marchand, Loı̈c Le , Phipps, Amanda I. , Schmit, Stephanie L. , Gallinger, Steven , Pai, Rish K. , Samadder, N. Jewel , Thorne, Heather , Maclnnis, Robert , Jenkins, Mark A , Milne, Roger L , John, Esther M , Andrulis, Irene L , Colonna, Sarah V , Phillips, Kelly-Anne , Marchand, Loïc Le , Schmit, Stephanie L , Macrae, Finlay A , Buchanan, Daniel D , Gallinger, Steven , Pai, R K , Samadder, N Jewel , Giles, Graham G , Southey, Melissa C , Hopper, John L. , Terry, Mary Beth , MacInnis, Robert J. , Jenkins, Mark A. , Daly, Mary Beryl , Investigators, kConFab, Newcomb, Polly A. , Macrae, Finlay , Buchanan, Daniel D. , Giles, Graham G. , Southey, Melissa C. , Hopper, John L. , Terry, Mary Beth

Mayo Clinic

JNCI Cancer Spectrum | December 14, 2024 | Volume: 9 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae121 | PMID 39673461 Get It

Abstract Menopausal users of hormone replacement therapy (HRT) are at increased breast cancer risk and decreased colorectal cancer (CRC) risk compared with individuals who have never used HRT, but these opposing associations may differ by familial risk of breast cancer and CRC. We harmonized data from 3 cohorts and generated separate breast cancer and CRC familial risk scores based on cancer family history. We defined moderate or strong family history as a risk score of 0.4 or higher, where 0.4 was equivalent to a 50-year-old woman with 1 parent diagnosed with either breast cancer or CRC at 55 years of age. Of 24 486 women assessed, 1243 and 405 were diagnosed with incident breast cancer and CRC, respectively. For breast cancer, menopausal HRT ever use versus never use hazard ratios were 1.27 (95% CI = 1.11 to 1.45) for a breast cancer familial risk score below 0.4 and 1.01 (95% CI = 0.82 to 1.25) for a breast cancer familial risk score of 0.4 or higher (Pdifference = .08). For CRC, menopausal HRT hazard ratios were 0.63 (95% CI = 0.50 to 0.78) for a CRC familial risk score below 0.4 and 1.21 (95% CI = 0.73 to 2.00) for a CRC familial risk score of 0.4 or higher (Pdifference = .03). Associations with menopausal HRT use that apply to the general population may not hold for women at moderate or strong familial risk of these cancers.
An international Delphi consensus on patient preparation for metabolic and bariatric surgery
Clyde, Danielle , Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Catalain, Copaescu, Clare, Ken , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Ghanem, Omar M. , Hopkins, George, Kothari, Shanu N. , Kow, Lilian , Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Saliminen, Paulina, Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Tahrani, Abd A. , Voon, Kelvin , Welbourn, Richard , Lamb, Peter , Mahawar, Kamal , Yang, Wah , Salminen, Paulina , Kermansaravi, Mohammad , Zerrweck, Carlos , Yang, Wah , Byrne, James Patrick , Cameron, David, Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Husain, Farah Anwari , Joyce, Brian, Miras, Alexander Dimitri , Moussa, Osama , Neto, Manoel Galvão , Parmar, Chetan D. , Peterli, Ralph , Stenberg, Erik , Vilallonga, Ramón , Robertson, Andrew G.

Mayo Clinic

Clinical Obesity | December 14, 2024 | Volume: 15 | Issue: 2 | Pages: No page available

10.1111/cob.12722 | PMID 39673462 Get It

SummaryGlobal obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m2), is performed globally over 500 000 times annually, offering significant metabolic benefits beyond weight loss. However, varying eligibility criteria globally impact patient care and healthcare resources. Updated in 2022, ASMBS and IFSO guidelines aim to standardise MBS indications, reflecting current understanding and emphasising comprehensive preoperative assessments. Yet, clinical variability persists, necessitating consensus‐based recommendations. This modified Delphi study engaged 45 global experts to establish consensus on perioperative management in MBS. Experts selected from bariatric societies possessed expertise in MBS and participated in a two‐round Delphi protocol. Consensus was achieved on 90 of 169 statements (53.3%), encompassing multidisciplinary team composition, patient selection criteria, preoperative testing, and referral pathways. The agreement highlighted the critical role of comprehensive preoperative assessments and the integration of healthcare professionals in MBS. These findings offer essential insights to standardise perioperative practices and advocate for evidence‐based guidelines in MBS globally. The study underscores the need for unified protocols to optimise outcomes and guide future research in MBS.
Designing Program Requirements for a New Generation of Pediatricians: A Writing Group’s Journey
Buchter, Susie, Daniels, Gabriel , Dewar, Stephanie , Fischer, Caroline, Homme, Jason H. , Kesselheim, Jennifer C. , Rosenberg, Adam, Duncan, Shawna Segraves, Shaw, Judith S. , Dewar, Stephanie B , Homme, Jason , Kesselheim, Jennifer , Shaw, Judith , Duncan, Shawna Segraves

Mayo Clinic

Journal of Graduate Medical Education | December 13, 2024 | Volume: 16 | Issue: 6 | Pages: 762-768

10.4300/jgme-d-24-00932.1 | PMID 39677307 Get It